ArticleRSC advances2025

Potent EGFR/PARP-1 inhibition by spirooxindole-triazole hybrids for targeted liver cancer therapy.

Mohamed S Nafie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.